<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39489523</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1326-5377</ISSN><JournalIssue CitedMedium="Internet"><Volume>221 Suppl 9</Volume><PubDate><Year>2024</Year><Month>Nov</Month><Day>04</Day></PubDate></JournalIssue><Title>The Medical journal of Australia</Title><ISOAbbreviation>Med J Aust</ISOAbbreviation></Journal><ArticleTitle>Persistent symptoms after COVID-19: an Australian stratified random health survey on long COVID.</ArticleTitle><Pagination><StartPage>S12</StartPage><EndPage>S17</EndPage><MedlinePgn>S12-S17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5694/mja2.52473</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the impact of persistent symptoms after coronavirus disease 2019 (COVID-19) in an Australian population.</AbstractText><AbstractText Label="DESIGN, SETTING, PARTICIPANTS" NlmCategory="METHODS">We conducted a statewide health survey of a stratified random sample of adults who had had a confirmed acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19-positive group) and their close contacts (control group). The sample was drawn from Victoria's COVID-19 database between January 2020 and October 2022. Data were collected from 12&#x2009;688 survey respondents between September 2022 and April 2023 (11&#x2009;174 in the COVID-19-positive group and 1514 in the control group).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Persistent new symptoms, recovery, and daily function using validated questionnaires for fatigue, neurocognitive symptoms, anxiety, depression and quality of life.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At a mean of 12.6 months after infection, 4560 respondents in the COVID-19-positive group (39.1%; 95% CI, 37.9-40.3%) reported at least one persistent new symptom, compared with 216 respondents in the control group (20.8%; 95% CI, 18.5-23.1%). A total of 1656 respondents (14.2%; 95% CI, 13.4-15.0%) were classified as having clinical long COVID using the criteria of at least one persistent new symptom and less than 80% recovery three months after the infection. Of the respondents with clinical long COVID, 535 (3.2%; 95% CI, 2.6-3.8%) reported at least moderate problems with usual activities at 12 months after their infection. The proportion of respondents with clinical long COVID was lower for those with more recent infections. The risk factors for clinical long COVID were female sex, age 40-49 years, infection severity, chronic illness, and past anxiety or depression. Factors associated with a decreased risk of having clinical long COVID included infection when the Omicron strain was dominant and infection when the Delta strain was dominant, as compared with when the ancestral strain of the virus was dominant.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Persistent symptoms after COVID-19 are common, though with a lower incidence following infection from less virulent strains. Although long COVID can be largely managed in primary care, a minority of people who have persistent symptoms and impaired function may require specialist care pathways, the effectiveness of which should be a focus of future research.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Medical Journal of Australia published by John Wiley &amp; Sons Australia, Ltd on behalf of AMPCo Pty Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Royal Melbourne Hospital, Melbourne, VIC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Melbourne, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emerson</LastName><ForeName>Lance</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Health, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irving</LastName><ForeName>Louis B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Royal Melbourne Hospital, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tippett</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9038-6952</Identifier><AffiliationInfo><Affiliation>Clinic Nineteen, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pullin</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Health, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Health, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watters</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Deakin University, Geelong, VIC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Safer Care Victoria, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Adina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Health, Melbourne, VIC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Med J Aust</MedlineTA><NlmUniqueID>0400714</NlmUniqueID><ISSNLinking>0025-729X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="Y">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014739" MajorTopicYN="N" Type="Geographic">Victoria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>4</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>4</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>3</Day><Hour>20</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39489523</ArticleId><ArticleId IdType="doi">10.5694/mja2.52473</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et&#xa0;al. Attributes and predictors of long COVID. Nat Med 2021; 27: 626&#x2010;631.</Citation></Reference><Reference><Citation>Castanares&#x2010;Zapatero D, Chalon P, Kohn L, et&#xa0;al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med 2022; 54: 1473&#x2010;1487.</Citation></Reference><Reference><Citation>World Health Organization. Post COVID&#x2010;19 condition (long COVID). 7 Dec 2022. https://www.who.int/europe/news&#x2010;room/fact&#x2010;sheets/item/post&#x2010;COVID&#x2010;19&#x2010;condition (viewed Oct 2023).</Citation></Reference><Reference><Citation>Nittas V, Gao M, West EA, et&#xa0;al. Long COVID through a public health lens: an umbrella review. Public Health Rev 2022; 43: 1604501.</Citation></Reference><Reference><Citation>Mudgal SK, Gaur R, Rulaniya S, et&#xa0;al. Pooled prevalence of long COVID&#x2010;19 symptoms at 12 months and above follow&#x2010;up period: a systematic review and meta&#x2010;analysis. Cureus 2023; 15: e36325.</Citation></Reference><Reference><Citation>Office for National Statistics (UK). Prevalence of ongoing symptoms following coronavirus (COVID&#x2010;19) infection in the UK: 2 February 2023. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/2february2023 (viewed Aug 2023).</Citation></Reference><Reference><Citation>Australian Institute of Health and Welfare. Long COVID in Australia &#x2013; a review of the literature (AIHW Cat. No. PHE 318). Canberra: AIHW, 2022. https://www.aihw.gov.au/reports/covid&#x2010;19/long&#x2010;covid&#x2010;in&#x2010;australia&#x2010;a&#x2010;review&#x2010;of&#x2010;the&#x2010;literature/summary (viewed Oct 2023).</Citation></Reference><Reference><Citation>World Health Organization. WHO COVID&#x2010;19 dashboard. https://covid19.who.int (viewed Oct 2023).</Citation></Reference><Reference><Citation>Biddle N, Korda R. The experience of COVID&#x2010;19 in Australia, including long&#x2010;COVID &#x2013; evidence from the COVID&#x2010;19 Impact Monitoring Survey series. Canberra: Australian National University, 2022. https://csrm.cass.anu.edu.au/research/publications/experience&#x2010;covid&#x2010;19&#x2010;australia&#x2010;including&#x2010;long&#x2010;covid&#x2010;evidence&#x2010;covid&#x2010;19&#x2010;impact (viewed Oct 2023).</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et&#xa0;al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335: 806&#x2010;808.</Citation></Reference><Reference><Citation>Heidari S, Babor TF, De Castro P, et&#xa0;al. Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev 2016; 1: 2.</Citation></Reference><Reference><Citation>Amin&#x2010;Chowdhury Z, Ladhani SN. Causation or confounding: why controls are critical for characterizing long COVID. Nat Med 2021; 27: 1129&#x2010;1130.</Citation></Reference><Reference><Citation>Docherty AB, Harrison EM, Green CA, et&#xa0;al. Features of 20&#x2009;133 UK patients in hospital with COVID&#x2010;19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020; 369: m1985.</Citation></Reference><Reference><Citation>Herdman M, Gudex C, Lloyd A, et&#xa0;al. Development and preliminary testing of the new five&#x2010;level version of EQ&#x2010;5D (EQ&#x2010;5D&#x2010;5L). Qual Life Res 2011; 20: 1727&#x2010;1736.</Citation></Reference><Reference><Citation>Cella D, Lai JS, Nowinski CJ, et&#xa0;al. Neuro&#x2010;QOL: brief measures of health&#x2010;related quality of life for clinical research in neurology. Neurology 2012; 78: 1860&#x2010;1867.</Citation></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD&#x2010;7. Arch Intern Med 2006; 166: 1092&#x2010;1097.</Citation></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JB. The PHQ&#x2010;9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606&#x2010;613.</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, et&#xa0;al. A clinical case definition of post&#x2010;COVID&#x2010;19 condition by a Delphi consensus. Lancet Infect Dis 2022; 22: e102&#x2010;e7.</Citation></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41&#x2010;55.</Citation></Reference><Reference><Citation>Australian Bureau of Statistics. Snapshot of Victoria. Canberra: ABS, 2022. https://www.abs.gov.au/articles/snapshot&#x2010;vic&#x2010;2021 (viewed Oct 2023).</Citation></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau&#x2010;Hyam M, et&#xa0;al. Persistent COVID&#x2010;19 symptoms in a community study of 606,434 people in England. Nat Commun 2022; 13: 1957.</Citation></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et&#xa0;al. Symptoms and risk factors for long COVID in non&#x2010;hospitalized adults. Nat Med 2022; 28: 1706&#x2010;1714.</Citation></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et&#xa0;al. Immunological dysfunction persists for 8 months following initial mild&#x2010;to&#x2010;moderate SARS&#x2010;CoV&#x2010;2 infection. Nat Immunol 2022; 23: 210&#x2010;216.</Citation></Reference><Reference><Citation>Wang S, Quan L, Chavarro JE, et&#xa0;al. Associations of depression, anxiety, worry, perceived stress, and loneliness before infection with risk of post&#x2010;COVID&#x2010;19 conditions. JAMA Psychiatry 2022; 79: 1081&#x2010;1091.</Citation></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, et&#xa0;al. Trajectory of long COVID symptoms after COVID&#x2010;19 vaccination: community based cohort study. BMJ 2022; 377: e069676.</Citation></Reference><Reference><Citation>Kim Y, Bae S, Chang HH, Kim SW. Long COVID prevalence and impact on quality of life 2 years after acute COVID&#x2010;19 [author correction]. Sci Rep 2023; 13: 11960.</Citation></Reference><Reference><Citation>House of Representatives Standing Committee on Health, Aged Care and Sport. Sick and tired: casting a long shadow. Inquiry into long COVID and repeated COVID infections. Canberra: Commonwealth of Australia, 2023. https://www.aph.gov.au/Parliamentary_Business/Committees/House/Health_Aged_Care_and_Sport/LongandrepeatedCOVID/Report (viewed Oct 2023).</Citation></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et&#xa0;al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021; 38: 101019.</Citation></Reference><Reference><Citation>Cutler DM. The costs of long COVID. JAMA Health Forum 2022; 3: e221809.</Citation></Reference><Reference><Citation>Naidu SB, Shah AJ, Saigal A, et&#xa0;al. The high mental health burden of &#x201c;Long COVID&#x201d; and its association with on&#x2010;going physical and respiratory symptoms in all adults discharged from hospital. Eur Respir J 2021; 57: 2004364.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>